Brief: Theseus Pharmaceuticals Reports Initial Dose Escalation Data From Ongoing Phase 1/2 Trial Of The-630 In Patients With Advanced GIST
25/05/2023 23:17
May 25 (Reuters) - Theseus Pharmaceuticals Inc THRX.O :
* THESEUS PHARMACEUTICALS REPORTS INITIAL DOSE ESCALATION
DATA
FROM ONGOING PHASE 1/2 TRIAL OF THE-630 IN PATIENTS WITH
ADVANCED GIST
* THESEUS PHARMACEUTICALS INC - -630 DEMONSTRATES
ENCOURAGING
SAFETY PROFILE THROUGH COHORT 6 (18 MG), SUPPORTIVE OF CONTINUED
DOSE ESCALATION
Source text for Eikon: ID:nPn6XvpjLa
Further company coverage: THRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Theseus Pharmaceuticals
See all newsU.S. STOCKS ON THE MOVE-Cidara Therapeutics, Senti Bio, Lumentum Holdings
U.S. STOCKS ON THE MOVE-Newmont Corp, Ansys, Karuna Therapeutics
Theseus Pharma rises as Concentra Biosciences agrees to take it private
Brief: Theseus Pharmaceuticals To Be Acquired by Concentra Biosciences
Brief: Theseus Pharmaceuticals Inc Says As Part Of A Reduction In Workforce, Co Terminated Employment Of Timothy P. Clackson, Co's CEO, Effective As Of Dec 7